| Nanoplatforms for cancer theranostics | Lifetime | 19 | CN 12 | 99.90 |
| Nanoparticle-Based Drug Delivery | Lifetime | 53 | CN 15 | 99.69 |
| Advanced Nanomaterials in Catalysis | Lifetime | 62 | CN 38 | 99.55 |
| Extracellular vesicles in disease | Lifetime | 61 | CN 14 | 99.19 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 77 | CN 2 | 99.30 |
| Luminescence Properties of Advanced Materials | Lifetime | 185 | CN 86 | 98.82 |
| Luminescence and Fluorescent Materials | Lifetime | 234 | CN 134 | 99.09 |
| RNA Interference and Gene Delivery | Lifetime | 449 | CN 87 | 98.74 |
| Advanced biosensing and bioanalysis techniques | Lifetime | 759 | CN 338 | 98.55 |
| Immune cells in cancer | Lifetime | 340 | CN 33 | 98.01 |
| Photoacoustic and Ultrasonic Imaging | Lifetime | 275 | CN 40 | 97.88 |
| Ferroptosis and cancer prognosis | Lifetime | 343 | CN 170 | 96.17 |
| Peptidase Inhibition and Analysis | Lifetime | 805 | CN 24 | 97.44 |
| Nanocluster Synthesis and Applications | Lifetime | 363 | CN 189 | 97.36 |
| Photodynamic Therapy Research Studies | Lifetime | 323 | CN 53 | 96.61 |
| Graphene and Nanomaterials Applications | Lifetime | 939 | CN 384 | 95.35 |
| Phagocytosis and Immune Regulation | Lifetime | 513 | CN 29 | 93.05 |
| Nanoplatforms for cancer theranostics | 2021-2025 | 2 | CN 2 | 99.99 |
| Nanoparticle-Based Drug Delivery | 2021-2025 | 3 | CN 1 | 99.91 |
| Advanced Nanomaterials in Catalysis | 2021-2025 | 9 | CN 8 | 99.76 |
| Extracellular vesicles in disease | 2021-2025 | 15 | CN 11 | 99.37 |
| Immunotherapy and Immune Responses | 2021-2025 | 21 | CN 4 | 99.54 |
| Luminescence Properties of Advanced Materials | 2021-2025 | 12 | CN 10 | 99.49 |
| Immune cells in cancer | 2021-2025 | 20 | CN 12 | 99.22 |
| RNA Interference and Gene Delivery | 2021-2025 | 16 | CN 9 | 99.41 |
| Luminescence and Fluorescent Materials | 2021-2025 | 48 | CN 43 | 99.38 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 25 | CN 1 | 99.02 |
| Peptidase Inhibition and Analysis | 2021-2025 | 51 | CN 8 | 98.71 |
| Advanced biosensing and bioanalysis techniques | 2021-2025 | 206 | CN 147 | 98.65 |
| Phagocytosis and Immune Regulation | 2021-2025 | 18 | CN 6 | 95.65 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 417 | CN 69 | 98.36 |
| Photodynamic Therapy Research Studies | 2021-2025 | 51 | CN 35 | 96.77 |
| Ferroptosis and cancer prognosis | 2021-2025 | 232 | CN 185 | 96.23 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 253 | CN 22 | 95.57 |
| Cancer Research and Treatments | 2021-2025 | 106 | CN 58 | 94.04 |
| Photoacoustic and Ultrasonic Imaging | 2021-2025 | 154 | CN 72 | 94.82 |
| interferon and immune responses | 2021-2025 | 150 | CN 79 | 93.28 |
| Graphene and Nanomaterials Applications | 2021-2025 | 260 | CN 62 | 94.45 |
| Nanocluster Synthesis and Applications | 2021-2025 | 225 | CN 170 | 93.88 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 109 | CN 37 | 86.82 |
| Lung Cancer Research Studies | 2021-2025 | 861 | CN 186 | 90.65 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 905 | CN 89 | 86.92 |
| Supramolecular Self-Assembly in Materials | 2021-2025 | 585 | CN 319 | 83.59 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 227 | CN 67 | 80.59 |
| Sulfur Compounds in Biology | 2021-2025 | 464 | CN 328 | 79.55 |
| Supramolecular Chemistry and Complexes | 2021-2025 | 554 | CN 297 | 79.41 |
| Galectins and Cancer Biology | 2021-2025 | 552 | CN 143 | 73.20 |
| Molecular Communication and Nanonetworks | 2021-2025 | 691 | CN 259 | 55.68 |
